Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 second quarter results for the period ending January 31, 2022.

2022-03-16 Q2 PR